Lumen Press Releases

Back to News

10/4/2022 Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria
4/19/2022 KYORIN and Lumen Bioscience Reach Collaboration Research Agreement
4/15/2022 Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection
3/21/2022 Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
12/22/2021 Lumen Bioscience Releases Data on Potent, Orally Delivered Biologic Drug Cocktail for Preventing C. difficile Infection
11/3/2021 Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms
10/5/2021 Lumen Bioscience Awarded Federal Funding to Advance Covid-19 Antibody Cocktail through Phase 2 Clinical Evaluation
8/31/2021 Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence
8/10/2021 Lumen Bioscience Teams with Google to Apply Machine Learning to Biologics Manufacturing
7/12/2021 Lumen Bioscience Expands Biologics Manufacturing Capacity with Lease of Historic Seattle Bakery
6/16/2021 Lumen Bioscience and Novo Nordisk Enter into Research Collaboration to Explore Novel Strategies to Deliver Oral Biologics for Cardiometabolic Disease
4/21/2021 Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team